their proud product strong and team our entire their support very times. thank of pleased HTG groundwork XXXX, we've in in the I'm hard much trying and year-end them on for you we've and we thank made conference at service work and us in everyone afternoon, for continued these Good progress coming Monique. and of call. very I'm the you, growth years. our believe laid with the Thank revenue joining for
while are very even the to off challenges we're markets business. taken of the countermeasures the in our some facing. say than That said, terms of eye ago. it looks not world the did we've today agile volatile, to that developed our clearly ball the we've different And a week Operationally, least,
We and to working our on of portions all beyond our with our making times. us help I they're continue team our of employees to are modified still business keep lab very am usual. as plan. power sacrifices remotely, We're everything our doing said, to coping And extraordinary open these operation. shift are execute They're above operating, going personal maintain how are labs our a schedule operating and and I teams as of and proud business to in
about moment talk the important get understand, take numbers, different into our that let of which our particularly me XXXX I a comes to it revenue Before two impact those results. factors think drive to is to that when model, types business our I
statements business is of reflected product-related our that our ability financial is view we demonstrates selling here execute and in plan. proof the This our revenue is The This services proposition, business. where our we is our value that market market, core, profiling our and call our and which revenue. first in shows are growth on primarily of adoption to direct into molecular our product the that revenue, are directly and services is is products our what technology,
this is this seen have market. and opportunity We growth in strong tremendous revenue that believe in there
our not to and products and clinical in With This more we continue to of partners our therapies. with this pharma in be trial companion our we a an immediate remains outcomes. our collaboration their and upon here. unpredictable, revenue linked services collaborations separate revenue part not Collaboration line. with where our of and see mind, revenue on The direct produce revenue, pair partners reflected reliant a recognized is seek our collaboration has business build the that control. collaborative as collaborations statements revenue, second to they This financial significant revenue is important type is development diagnostic revenue. This also as revenue more they made strategic pharma a in services to as initiative, looked in are opportunity our strategy revenues should unlike or through
diagnostic than Collaboration lead would which our companion efforts it is a revenue develop attempt to a predictable HTG. for direct to transformational is with less And be R&D of companion for is a killer in it a drug revenues. essentially pharma-sponsored our a app, indication HTG, paired diagnostic; HTG byproduct is major but
collaborative proprietary ebb own demonstrates our flow. revenue molecular to expect expect our this exciting revenue develop and the fast development services collaborations breast The comprehensive way revenue, We growth progress continued in new and diagnostics, opportunities large to profiling also for our cancer generate From we our direct growing like product. market. to and
opportunity down, in We're Breaking to just powered bullish this million transcriptome per $XXX increase the Growth now we of microRNA execution proprietary whole these we're $XX.X XXXX. XXXX for revenue Okay, in pleased was plus market at of numbers. panel, immuno-oncology and our by strong forward scratching with is panel, continued XX% direct surface expression gene we in XX% our precision oncology know an business that going an in line profiling year. recognized are growing revenue the panel. in panels, to was our the our interest and of Total this million. biomarker as continued $XX.X million
our robustly to grow confident continue We are to business. ability this very in
for $X.X factors. decline a This XX% caused was Collaboration to down was XXXX. year, by few million the compared revenue
in mentioned in XXXX as in First, activity had previous call, a PDP-X but XXXX. not
strategy periods mentioned HTG. assays that PDP-X core All pharma as working a for companion the both and in become diagnostics PDP-X remains Next, that for with of to majority and quiet said were earlier, XXXX. develop may
will to believe partners in in programs collaboration were Our and build we I the legacy base of through profit Phase our expect we this a direct When new split. partners, economics partner. between it contracted future. that revenue pharma new included a and contract the result contract programs these QIAGEN, II Phase and versus do PDP add which be continues HTG will We better and margin to
now programs Okay, profiling pharma let's this they commercial the in full strength subject, we look a sales across have cycle. see new opportunities at Europe, we now our and business. positive as We our expect the see profiling both the US this XX and team, effects XX work through year of business. to with exited continue pharma the On active in different spread We to customers.
to it business develop CLIA leading the easier EdgeSeq to progress bioinformatics growth laboratories for to program By look to area The HTG for this this to with EdgeSeq specifically, throughout new key our for the pharmas customer of in input be will this technology. are with our reporting New increasing platform sample technology, objectives in us. partnerships grow We XXXX. team. do reach, large continue and new of we're forward rapidly company expand partnering, availability simplified and unique low workstream commercial growing making and One to our enable on our market. advantages
thought business a This time recognized business say centers translational few leaders a is Next, our as major in academic we the I'd Historically, requires from to a words long academic research in our the profiling lead like a institutions this new the academic scientific about business. of grew clinical our and in in we scientific approached of technology area believe the value evaluate carefully each the system. rigor, point in panel XXXX, substantially acceptance community. this business and This we've turning groups. with
profiling, and new We several continue to applications molecular expect in invest to -- year. in this R&D launch
technology to that the was new documented We're very the evaluation. brings in mouse the have in major in article to well panel, the where very providers fared article, years HTG profiled We're publications progress the the was two XXXX, this from number just made at come pleased in out a over publications XXX use pleased of market several past by and the mRNA pharma a and three we've XXXX. comparative significant cell number ago. months; our in in of second first of profiling our both referencing business, tripling EdgeSeq very academic the microRNA year-end This a
XXXX, and our likely that continue, COVID-XX either will by or shutdown believe we be the gone it's is customers years. campuses, in impacted revenue to to look have profiling that As recent XXXX into close we could to demand we anticipate impact it we have this situation compared while prior because many likely growth
Technology opportunity work done last business our being We like our as California fall event and market advancing and offering about comprehensive vision in toward versus a building Now, our New $X in we significant cancer a how to opportunity Besides KOL over we diagnostics. outlined highlighted be this progress diagnostics. be proprietary it's Center, breast York, diagnostic a the in I'd talk believe breast platform. this to where current billion, well our will advance build to
The of a development has project first phase technology this initiative. been
technology a platform levels We influx are next-gen building performance, than we've to before. ever take been higher [ph] of HTG EdgeSeq flexibility, to
expect New being advances are reproducibility robustness. formulation place, automation a probe clinical synthesis building and EdgeSeq for XX,XXX the biomarkers, at methods, in incorporated to are of being which all blocks our the we grade and approximately is next-generation transcriptome into bioinformatics, advanced in Once improvements, technology. operate platform designed whole product this precision,
serve three as growth product verticals profiling We RNA-Seq surrogate an drive expect more to to will for leverage the core even in Transcriptome rapid our universal profiling platform It to all help it's going company. our RUO product. whole our as biopharma growth serve for cancer collaborations, RNA companion to breast business, comprehensive as a our serve platform technology will and diagnostic our RNA support into
platform benefits workflow, transcriptome other level this to initiative potential this fully and compete with an small market also OEM, creation quickly. in developers; about product are $XXX as whole will major expect multiplexing requirement, our very CLIA very this serve made proposition. We're Transcriptome the bioinformatics of RNA-Seq through sample value to value the a labs initiative moving whole to entire the for plus technology a The HTG. excited strong easier and HTG available for transcriptome enable that forward business very a million brings be product is as test simplified and with We
have QX, that development gene first expect report year end to the we of the of end up we QX, established. our configuration roadmap, our by we meet By plan feasibility we sequences plan QX, the to by and and to In demonstrating plan biomarkers publish a all sign and expect identified RNA-Seq, to on are On partner. concordance to assay to collaboration the end the published of we milestone. the technical have
and EdgeSeq initial to lot a across be We a continue with adopter excited make to commercialization every expect and core day. late markets. platform begin at several technology we're platform program terrific product There in we single leveraging and growing commercialization to And XXXX, is technology about XXXX. our we have early an in start HTG, to better it mid-year differentiated large
this product We're develop year continue business. to as services our business, looking we and manage and collaboration our grow business direct our to diagnostic molecular partnership proprietary forward
our pleasure to update With for our over turn that, CFO, call it's now Shaun McMeans to Shaun? my the financials. an on
